New Rhein Healthcare

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to traditional BPH treatments, including medication and surgery. It can be placed in under 10 minutes in an office setting, using local anesthesia and without the need for surgical incisions, heating, or tissue removal. Butterfly Medical's patented device aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trial results have shown promise, with successful openings of blocked urethras and no reported side effects in patients. The company is set to conduct further clinical studies at leading medical centers in Europe.

American Injectables is a sterile injectable manufacturer of parenteral drugs with a world-class facility focused on ready-to-use pre-filled syringes and vials.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for the treatment of peripheral nerve injuries (PNI). The company offers a range of products, including AxoFuse, a nerve repair system designed to prevent nerve degeneration and limb atrophy; AxoTrim, a surgical instrument for preparing nerves for suturing; and AxoBond, which secures surgically repaired nerves during recovery. Additionally, Neuraptive is working on NTX-001, a drug-device product intended for use in surgical nerve repairs and reconstructive procedures. Founded in 2016, the company aims to address the unmet medical needs of patients and physicians dealing with acute nerve injuries. Neuraptive is headquartered in Lafayette, Colorado, with additional offices in Philadelphia, Pennsylvania, and Louisville, Colorado.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for the treatment of peripheral nerve injuries (PNI). The company offers a range of products, including AxoFuse, a nerve repair system designed to prevent nerve degeneration and limb atrophy; AxoTrim, a surgical instrument for preparing nerves for suturing; and AxoBond, which secures surgically repaired nerves during recovery. Additionally, Neuraptive is working on NTX-001, a drug-device product intended for use in surgical nerve repairs and reconstructive procedures. Founded in 2016, the company aims to address the unmet medical needs of patients and physicians dealing with acute nerve injuries. Neuraptive is headquartered in Lafayette, Colorado, with additional offices in Philadelphia, Pennsylvania, and Louisville, Colorado.

Softhale NV develops inhalation products for respiratory treatment. It offers Soft Mist Inhalation(SMI) device for lungs. The company was founded in 2016 and is based in Diepenbeek, Belgium.

Chase Pharmaceuticals Corporation, established in 2007 and based in Washington, D.C., is a specialty pharmaceutical company dedicated to developing innovative treatments for Alzheimer’s disease and related neurodegenerative disorders. The company focuses on the clinical development of CPC-252, a transdermal formulation intended for the treatment of Alzheimer’s disease and Parkinsonism dementia. Chase Pharmaceuticals aims to bridge advancements in basic neurosciences with the pressing medical needs associated with neuropsychiatric diseases. The company identifies promising drug candidates, enhances their value to prepare for global registration, and collaborates with commercial partners for licensing. Alzheimer’s disease represents a significant unmet medical need, with current treatments offering only marginal symptom improvement and high dropout rates. The founders of Chase have developed a patented combination of established pharmaceuticals that they believe could enhance the symptomatic management of Alzheimer’s disease, which has become a leading cause of death in the U.S. and presents a growing economic burden as the population ages.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.